HRP20161036T1 - IMIDAZOPIRAZIN Syk INHIBITORI - Google Patents
IMIDAZOPIRAZIN Syk INHIBITORI Download PDFInfo
- Publication number
- HRP20161036T1 HRP20161036T1 HRP20161036TT HRP20161036T HRP20161036T1 HR P20161036 T1 HRP20161036 T1 HR P20161036T1 HR P20161036T T HRP20161036T T HR P20161036TT HR P20161036 T HRP20161036 T HR P20161036T HR P20161036 T1 HRP20161036 T1 HR P20161036T1
- Authority
- HR
- Croatia
- Prior art keywords
- pharmaceutically acceptable
- compound
- acceptable salt
- leukemia
- lymphoma
- Prior art date
Links
- ZKAMEFMDQNTDFK-UHFFFAOYSA-N 1h-imidazo[4,5-b]pyrazine Chemical compound C1=CN=C2NC=NC2=N1 ZKAMEFMDQNTDFK-UHFFFAOYSA-N 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 19
- 150000003839 salts Chemical class 0.000 claims 19
- 206010028980 Neoplasm Diseases 0.000 claims 7
- 201000011510 cancer Diseases 0.000 claims 7
- 238000000034 method Methods 0.000 claims 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 230000000694 effects Effects 0.000 claims 5
- 210000004027 cell Anatomy 0.000 claims 4
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 4
- 238000000338 in vitro Methods 0.000 claims 4
- 208000032839 leukemia Diseases 0.000 claims 4
- 208000003950 B-cell lymphoma Diseases 0.000 claims 3
- 206010025323 Lymphomas Diseases 0.000 claims 3
- 239000013543 active substance Substances 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 2
- 208000017604 Hodgkin disease Diseases 0.000 claims 2
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 2
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 claims 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 2
- 208000034578 Multiple myelomas Diseases 0.000 claims 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 2
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims 2
- 230000000172 allergic effect Effects 0.000 claims 2
- 208000010668 atopic eczema Diseases 0.000 claims 2
- 208000037979 autoimmune inflammatory disease Diseases 0.000 claims 2
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims 2
- 210000003719 b-lymphocyte Anatomy 0.000 claims 2
- 238000002512 chemotherapy Methods 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 230000007062 hydrolysis Effects 0.000 claims 2
- 238000006460 hydrolysis reaction Methods 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 101710181757 1,2-dihydroxy-3-keto-5-methylthiopentene dioxygenase Proteins 0.000 claims 1
- 101710094863 Acireductone dioxygenase Proteins 0.000 claims 1
- 208000004736 B-Cell Leukemia Diseases 0.000 claims 1
- 206010039085 Rhinitis allergic Diseases 0.000 claims 1
- 206010047112 Vasculitides Diseases 0.000 claims 1
- 206010047115 Vasculitis Diseases 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims 1
- 201000010105 allergic rhinitis Diseases 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000009277 hairy cell leukemia Diseases 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 206010028417 myasthenia gravis Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 201000003068 rheumatic fever Diseases 0.000 claims 1
- 230000035945 sensitivity Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
- C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
- G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- G01N2333/91205—Phosphotransferases in general
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Pulmonology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
Claims (17)
1. Spoj koji ima strukturu:
[image]
ili njegova farmaceutski prihvatljiva sol.
2. Farmaceutski pripravak naznačen time da sadrži:
spoj iz patentnog zahtjeva 1, ili njegovu farmaceutski prihvatljivu sol; i najmanje jedan farmaceutski prihvatljiv nosač, odabrano iz skupine koja se sastoji od nosača, adjuvanata, i ekscipijenata.
3. Spoj iz patentnog zahtjeva 1, ili njegova farmaceutski prihvatljiva sol, naznačen time da je za upotrebu u postupku liječenja osobe kojoj je to potrebno.
4. Spoj iz patentnog zahtjeva 1, ili njegova farmaceutski prihvatljiva sol, naznačen time da je za upotrebu u postupku liječenja osobe koja ima bolest koja reagira na inhibiciju Syk aktivnosti odabrano iz, liječenja karcinoma, uključujući B-stanični limfom i leukemiju, alergijske poremećaje, autoimune bolesti i inflamatorne bolesti kao što su: SLE, reumatični artritis, multiple vaskulitidi, idiopatska trombocitopenijska purpura (ITP), mijastenija gravis, alergijski rinitis, kronična opstruktivna bolest pluća ("COPD"), sindrom akutnog respiratornog poremećaja odraslih ("ARDs") i astma.
5. Spoj iz patentnog zahtjeva 1, ili njegova farmaceutski prihvatljiva sol, naznačen time da je za upotrebu u postupku liječenja osobe koja ima bolest izabranu iz grupe koja se sastoji od karcinoma, autoimune bolesti, inflamatorne bolesti, i alergijskog poremećaja.
6. Spoj iz patentnog zahtjeva 1, ili njegova farmaceutski prihvatljiva sol, naznačen time da je za upotrebu u postupku liječenja osobe koja ima karcinom.
7. Spoj iz patentnog zahtjeva 1, ili njegova farmaceutski prihvatljiva sol, naznačen time da je za upotrebu u postupku liječenja osobe koja ima limfom ili leukemiju.
8. Spoj iz patentnog zahtjeva 1, ili njegova farmaceutski prihvatljiva sol, naznačen time da je za upotrebu u postupku liječenja osobe koja ima bolest izabranu iz grupe koja se sastoji od B-ćelijskog limfoma, Hodgkin’sovog limfoma, ne-Hodgkin’sovog limfoma, leukemija "hairy" stanica (kronična limfoidna leukemija), multipli mijeloma, kronične mijeloidne leukemije, akutne mijeloidne leukemije, kronične limfocitne leukemije, i akutne limfocitne leukemije.
9. Spoj za upotrebu prema bilo kojem od patentnih zahtjeva od 3 do 8, ili njegova farmaceutski prihvatljiva sol, naznačen time da je dan osobi, u kombinaciji sa jednim ili više dodatnih aktivnih agenasa.
10. Spoj iz patentnog zahtjeva 1, ili njegova farmaceutski prihvatljiva sol, naznačen time da je za upotrebu u postupku liječenja karcinoma kod osobe kojoj je to potrebno, obuhvaća primjenu na ljude terapeutski efikasne količine spoja ili farmaceutski prihvatljive soli zajedno sa drugim aktivnim agensom korisnim u liječenju karcinoma.
11. Spoj za upotrebu prema patentnom zahtjevu 10, ili njegova farmaceutski prihvatljiva sol, naznačen time da se drugi aktivni agens primjenjuje prije, istovremeno, ili nakon tretmana sa spojem ili farmaceutski prihvatljivom soli.
12. Spoj za upotrebu prema patentnom zahtjevu 10 ili 11, ili njegova farmaceutski prihvatljiva sol, naznačen time da je karcinom limfom ili leukemija.
13. Spoj za upotrebu prema patentnom zahtjevu 12, ili njegova farmaceutski prihvatljiva sol, naznačen time da su limfom ili leukemija odabrani iz grupe koja se sastoji od B-ćelijskog limfoma, Hodgkin’sovog limfoma, ne-Hodgkin’sovog limfoma, leukemije "hairy" stanica (kronična limfoidna leukemija), multiple mijeloma, kronične mijeloidne leukemije, akutne mijeloidne leukemije, kronične limfocitne leukemije, i akutne limfocitne leukemije.
14. Spoj iz patentnog zahtjeva 1, ili njegova farmaceutski prihvatljiva sol, naznačen time da je za upotrebu u postupku povećanja osjetljivosti stanica karcinoma na kemoterapiju kod osobe koja je podvrgnuta kemoterapiji sa hemoterapeutskim agensom.
15. Postupak za utvrđivanje prisustva Syk-a u uzorku, naznačen time da sadrži kontakt uzorka sa spojem iz patentnog zahtjeva 1, ili njegovom farmaceutski prihvatljivom soli, pod uvjetima koji dozvoljavaju detekciju Syk aktivnosti, detektiranje nivoa Syk aktivnosti u uzorku, i iz toga utvrđivanje prisustva ili odsustva Syk-a u uzorku.
16. In vitro postupak za inhibiciju B-stanične aktivnosti naznačen time da obuhvaća kontakt stanica sa ekspresijom Syk sa Spojm iz patentnog zahtjeva 1, ili njegovim farmaceutski prihvatljivim solima, u količini dovoljnoj da detektirano umanji razinu B-stanične aktivnosti in vitro.
17. In vitro postupak za inhibiranje ATP hidrolize, naznačen time da postupak obuhvaća kontaktiranje stanica koje eksprimiraju Syk sa spojem iz patentnog zahtjeva 1, ili njegovim farmaceutski prihvatljivim solima, u količini dovoljnoj da detektirano umanji nivo ATP hidrolize in vitro.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12058708P | 2008-12-08 | 2008-12-08 | |
| US14051408P | 2008-12-23 | 2008-12-23 | |
| US24097909P | 2009-09-09 | 2009-09-09 | |
| EP13005979.3A EP2716157B1 (en) | 2008-12-08 | 2009-12-07 | Imidazopyrazine Syk inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20161036T1 true HRP20161036T1 (hr) | 2017-06-16 |
Family
ID=42242994
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20161036TT HRP20161036T1 (hr) | 2008-12-08 | 2016-08-17 | IMIDAZOPIRAZIN Syk INHIBITORI |
Country Status (30)
| Country | Link |
|---|---|
| US (7) | US8455493B2 (hr) |
| EP (3) | EP2716157B1 (hr) |
| JP (4) | JP5567587B2 (hr) |
| KR (4) | KR20170066685A (hr) |
| CN (2) | CN104744476B (hr) |
| AU (1) | AU2009325132B2 (hr) |
| BR (1) | BRPI0922225B1 (hr) |
| CA (1) | CA2746023C (hr) |
| CL (1) | CL2011001360A1 (hr) |
| CO (1) | CO6390078A2 (hr) |
| CY (1) | CY1118377T1 (hr) |
| DK (1) | DK2716157T3 (hr) |
| EA (3) | EA201690111A1 (hr) |
| ES (2) | ES2545610T3 (hr) |
| HR (1) | HRP20161036T1 (hr) |
| HU (1) | HUE030427T2 (hr) |
| IL (3) | IL213365A (hr) |
| LT (1) | LT2716157T (hr) |
| MX (1) | MX2011006091A (hr) |
| NZ (1) | NZ593459A (hr) |
| PE (2) | PE20140975A1 (hr) |
| PL (2) | PL2373169T3 (hr) |
| PT (2) | PT2373169E (hr) |
| RS (1) | RS55055B1 (hr) |
| SG (1) | SG171991A1 (hr) |
| SI (2) | SI2373169T1 (hr) |
| SM (1) | SMT201600267B (hr) |
| TW (2) | TWI478922B (hr) |
| VN (1) | VN28228A1 (hr) |
| WO (1) | WO2010068257A1 (hr) |
Families Citing this family (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ587039A (en) | 2008-02-13 | 2013-01-25 | Gilead Connecticut Inc | 6-aryl-imidazo[1, 2-a]pyrazine derivatives, method of making, and method of use thereof |
| US8455493B2 (en) | 2008-12-08 | 2013-06-04 | Gilead Connecticut, Inc. | Imidazopyrazine Syk inhibitors |
| EP3552607A3 (en) | 2008-12-08 | 2020-01-15 | Gilead Connecticut, Inc. | Imidazopyrazine syk inhibitors |
| US8450321B2 (en) | 2008-12-08 | 2013-05-28 | Gilead Connecticut, Inc. | 6-(1H-indazol-6-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo-[1,2-A]pyrazin-8-amine, or a pharmaceutically acceptable salt thereof, as a SYK inhibitor |
| JP5819831B2 (ja) * | 2009-08-17 | 2015-11-24 | インテリカイン， エルエルシー | 複素環式化合物およびそれらの使用 |
| KR101717809B1 (ko) * | 2010-03-11 | 2017-03-17 | 질레드 코네티컷 인코포레이티드 | 이미다조피리딘 ｓｙｋ 억제제 |
| US9127000B2 (en) | 2011-02-23 | 2015-09-08 | Intellikine, LLC. | Heterocyclic compounds and uses thereof |
| EP2706852B1 (en) | 2011-05-10 | 2018-08-22 | Merck Sharp & Dohme Corp. | Bipyridylaminopyridines as syk inhibitors |
| EP2707357B1 (en) | 2011-05-10 | 2017-01-18 | Merck Sharp & Dohme Corp. | Pyridyl aminopyridines as syk inhibitors |
| RU2013154412A (ru) | 2011-05-10 | 2015-06-20 | Мерк Шарп И Доум Корп. | Аминопиримидины в качестве ингибиторов syc |
| US9006444B2 (en) | 2011-10-05 | 2015-04-14 | Merck Sharp & Dohme Corp. | Phenyl carboxamide-containing spleen tyrosine kinase (SYK) inhibitors |
| EP2763976B1 (en) | 2011-10-05 | 2016-05-18 | Merck Sharp & Dohme Corp. | 2-pyridyl carboxamide-containing spleen tyrosine kinase (syk) inhibitors |
| US8987456B2 (en) | 2011-10-05 | 2015-03-24 | Merck Sharp & Dohme Corp. | 3-pyridyl carboxamide-containing spleen tyrosine kinase (SYK) inhibitors |
| AR090650A1 (es) | 2012-04-12 | 2014-11-26 | Alcon Res Ltd | Tratamiento para respuestas inflamatorias inducidas por microbios en el ojo |
| WO2013188856A1 (en) * | 2012-06-14 | 2013-12-19 | Gilead Connecticut, Inc. | Imidazopyrazine syk inhibitors |
| WO2013192128A1 (en) | 2012-06-20 | 2013-12-27 | Merck Sharp & Dohme Corp. | Imidazolyl analogs as syk inhibitors |
| US9242984B2 (en) | 2012-06-20 | 2016-01-26 | Merck Sharp & Dohme Corp. | Pyrazolyl derivatives as Syk inhibitors |
| WO2013192088A1 (en) | 2012-06-22 | 2013-12-27 | Merck Sharp & Dohme Corp. | SUBSTITUTED DIAZINE AND TRIAZINE SPLEEN TYROSINE KINASE (Syk) INHIBITORS |
| WO2013192098A1 (en) | 2012-06-22 | 2013-12-27 | Merck Sharp & Dohme Corp. | SUBSTITUTED PYRIDINE SPLEEN TYROSINE KINASE (Syk) INHIBITORS |
| CA2882134A1 (en) * | 2012-08-14 | 2014-02-20 | Gilead Calistoga Llc | Combination therapies for treating cancer |
| US9353066B2 (en) | 2012-08-20 | 2016-05-31 | Merck Sharp & Dohme Corp. | Substituted phenyl-Spleen Tyrosine Kinase (Syk) inhibitors |
| EP2900665B1 (en) | 2012-09-28 | 2018-01-03 | Merck Sharp & Dohme Corp. | Triazolyl derivatives as syk inhibitors |
| WO2014093191A1 (en) | 2012-12-12 | 2014-06-19 | Merck Sharp & Dohme Corp. | AMINO-PYRIMIDINE-CONTAINING SPLEEN TYROSINE KINASE (Syk) INHIBITORS |
| US9598405B2 (en) | 2012-12-21 | 2017-03-21 | Merck Sharp & Dohme Corp. | Thiazole-substituted aminopyridines as spleen tyrosine kinase inhibitors |
| WO2014176210A1 (en) | 2013-04-26 | 2014-10-30 | Merck Sharp & Dohme Corp. | Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors |
| EP2988749B1 (en) | 2013-04-26 | 2019-08-14 | Merck Sharp & Dohme Corp. | Thiazole-substituted aminopyrimidines as spleen tyrosine kinase inhibitors |
| EA201690127A1 (ru) * | 2013-07-30 | 2016-07-29 | Джилид Коннектикут, Инк. | Состав на основе ингибиторов syk |
| HRP20201582T1 (hr) | 2013-07-30 | 2021-02-19 | Kronos Bio, Inc. | Polimorf sik inhibitora |
| ES2656192T3 (es) | 2013-07-31 | 2018-02-26 | Gilead Sciences, Inc. | Inhibidores de SKY |
| PT3076976T (pt) | 2013-12-04 | 2020-12-07 | Kronos Bio Inc | Métodos para tratar cancros |
| WO2015094997A1 (en) | 2013-12-20 | 2015-06-25 | Merck Sharp & Dohme Corp. | Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors |
| US9670196B2 (en) | 2013-12-20 | 2017-06-06 | Merck Sharp & Dohme Corp. | Thiazole-substituted aminoheteroaryls as Spleen Tyrosine Kinase inhibitors |
| WO2015095445A1 (en) | 2013-12-20 | 2015-06-25 | Merck Sharp & Dohme Corp. | Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors |
| UY35898A (es) | 2013-12-23 | 2015-07-31 | Gilead Sciences Inc | ?compuestos inhibidores de syk y composiciones que los comprenden?. |
| US9290505B2 (en) | 2013-12-23 | 2016-03-22 | Gilead Sciences, Inc. | Substituted imidazo[1,2-a]pyrazines as Syk inhibitors |
| WO2015138273A1 (en) | 2014-03-13 | 2015-09-17 | Merck Sharp & Dohme Corp. | 2-pyrazine carboxamides as spleen tyrosine kinase inhibitors |
| US9796733B2 (en) | 2014-06-04 | 2017-10-24 | Merck Sharp & Dohme Corp. | Imidazo-pyrazine derivatives useful as soluble guanylate cyclase activators |
| TW201617074A (zh) * | 2014-07-14 | 2016-05-16 | 吉李德科學股份有限公司 | Ｓｙｋ（脾酪胺酸激酶）抑制劑 |
| KR20170029580A (ko) | 2014-07-14 | 2017-03-15 | 길리애드 사이언시즈, 인코포레이티드 | 암을 치료하기 위한 조합물 |
| TW201639573A (zh) * | 2015-02-03 | 2016-11-16 | 吉李德科學股份有限公司 | 有關治療癌症之合併治療 |
| US20160375019A1 (en) * | 2015-04-21 | 2016-12-29 | Gilead Sciences, Inc. | Treatment of chronic graft versus host disease with syk inhibitors |
| KR20180003614A (ko) * | 2015-05-12 | 2018-01-09 | 카리라 파마슈티컬스, 아이앤씨. | 바이사이클릭 화합물 |
| CN107709336B (zh) * | 2015-06-12 | 2021-06-22 | 杭州英创医药科技有限公司 | 作为Syk抑制剂和/或Syk-HDAC双重抑制剂的杂环化合物 |
| WO2017106564A1 (en) | 2015-12-17 | 2017-06-22 | Gilead Sciences, Inc. | Combination of a jak inhibitor and a syk inhibitor for treating cancers and inflammatory disorders |
| BR112019001365A2 (pt) * | 2016-07-28 | 2019-04-30 | Qbiotics Limited | método de tratamento |
| TW201822764A (zh) | 2016-09-14 | 2018-07-01 | 美商基利科學股份有限公司 | Syk抑制劑 |
| AU2017325844A1 (en) | 2016-09-14 | 2019-03-07 | Gilead Sciences, Inc. | SYK inhibitors |
| WO2018108083A1 (zh) * | 2016-12-12 | 2018-06-21 | 杭州英创医药科技有限公司 | 作为Syk抑制剂和/或Syk-HDAC双重抑制剂的杂环化合物 |
| WO2018195471A1 (en) | 2017-04-21 | 2018-10-25 | Gilead Sciences, Inc. | Syk inhibitors in combination with hypomethylating agents |
| US20200172529A1 (en) * | 2017-08-18 | 2020-06-04 | Beijing Hanmi Pharm. Co., Ltd. | Chemical Compound, Pharmaceutical Composition Thereof, and Use and Application Thereof |
| CN115028640A (zh) | 2017-08-25 | 2022-09-09 | 吉利德科学公司 | Syk抑制剂的多晶型物 |
| JP2020537678A (ja) | 2017-10-19 | 2020-12-24 | バイエル・アニマル・ヘルス・ゲーエムベーハー | 動物における疾患の治療および予防のための縮合ヘテロ芳香族ピロリドンの使用 |
| CN109879878A (zh) * | 2017-12-06 | 2019-06-14 | 朱允涛 | 一种氘代的咪唑并吡嗪类脾酪氨酸激酶（Syk）抑制剂 |
| US12012394B2 (en) | 2018-02-19 | 2024-06-18 | Washington University | Alpha-synuclein ligands |
| JP2021525802A (ja) | 2018-06-01 | 2021-09-27 | コーネル・ユニバーシティーＣｏｒｎｅｌｌ Ｕｎｉｖｅｒｓｉｔｙ | Ｐｉ３ｋに関連する疾患または障害に対する併用療法 |
| MX2021010131A (es) | 2019-02-22 | 2021-11-18 | Kronos Bio Inc | Formas sólidas de pirazinas condensadas a manera de inhibidores de syk. |
| WO2020188015A1 (en) | 2019-03-21 | 2020-09-24 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
| EP4054579A1 (en) | 2019-11-08 | 2022-09-14 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| CN115916782B (zh) * | 2020-06-01 | 2024-08-13 | 南京瑞捷医药科技有限公司 | 化合物及其作为脾酪氨酸激酶抑制剂的应用 |
| CA3193865A1 (en) | 2020-09-28 | 2022-03-31 | Jinhwa Lee | Indazoles as hematopoietic progenitor kinase 1 (hpk1) inhibitors and methods of using same |
| KR102560178B1 (ko) * | 2021-02-10 | 2023-07-27 | 재단법인 대구경북첨단의료산업진흥재단 | 이미다조[1,5-a]피라진 유도체 화합물 및 이를 유효성분으로 함유하는 암 또는 자가면역질환의 예방 또는 치료용 약학적 조성물 |
| CN113480543B (zh) * | 2021-07-07 | 2022-05-17 | 无锡市第二人民医院 | 2,6,8-多取代咪唑并[1,2-a]吡嗪及其合成方法和应用 |
| IL315365A (en) * | 2022-03-14 | 2024-11-01 | Purdue Research Foundation | Spleen tyrosine kinase inhibitor, composition and methods of use |
| KR20250037566A (ko) * | 2022-07-25 | 2025-03-17 | 셀진 코포레이션 | Irak3 결합제로서의 치환된 이미다조피라진 화합물 |
| WO2024102970A1 (en) * | 2022-11-11 | 2024-05-16 | Kronos Bio, Inc. | Compounds for modulating syk activity and e3 ubiquitin ligase activity |
Family Cites Families (76)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2607813B1 (fr) | 1986-12-05 | 1989-03-31 | Montpellier I Universite | Alkylamino-8 imidazo (1,2-a) pyrazines et derives, leur preparation et leur application en therapeutique |
| US5137876A (en) | 1990-10-12 | 1992-08-11 | Merck & Co., Inc. | Nucleoside antiviral and anti-inflammatory compounds and compositions and methods for using same |
| DE4327027A1 (de) | 1993-02-15 | 1994-08-18 | Bayer Ag | Imidazoazine |
| DE4337611A1 (de) | 1993-11-04 | 1995-05-11 | Boehringer Ingelheim Kg | Neue Benzoylguanidine, ihre Herstellung und ihre Verwendung in Arzneimitteln |
| DE4337609A1 (de) | 1993-11-04 | 1995-05-11 | Boehringer Ingelheim Kg | Neue Pyrazincarboxamidderivate, ihre Herstellung und ihre Verwendung in Arzneimitteln |
| FR2711993B1 (fr) | 1993-11-05 | 1995-12-01 | Rhone Poulenc Rorer Sa | Médicaments contenant des dérivés de 7H-imidazol[1,2-a]pyrazine-8-one, les nouveaux composés et leur préparation. |
| US6334997B1 (en) | 1994-03-25 | 2002-01-01 | Isotechnika, Inc. | Method of using deuterated calcium channel blockers |
| JP3696884B2 (ja) | 1994-03-25 | 2005-09-21 | アイソテクニカ、インコーポレーテッド | ジュウテリウム化による薬物の効能の増強 |
| FR2723373B1 (fr) | 1994-08-02 | 1996-09-13 | Rhone Poulenc Rorer Sa | Forme purifiee de streptogramines, sa preparation et les compositions pharmaceutiques qui la contiennent |
| WO1996034866A1 (en) | 1995-05-01 | 1996-11-07 | Fujisawa Pharmaceutical Co., Ltd. | Imidazo 1,2-a pyridine and imidazo 1,2-a pyridezine derivatives and their use as bone resorption inhibitors |
| US5593997A (en) | 1995-05-23 | 1997-01-14 | Pfizer Inc. | 4-aminopyrazolo(3-,4-D)pyrimidine and 4-aminopyrazolo-(3,4-D)pyridine tyrosine kinase inhibitors |
| US6249495B1 (en) | 1997-02-27 | 2001-06-19 | Matsushita Electric Industrial Co., Ltd. | Stepping motor control method and disk drive apparatus |
| SE9704404D0 (sv) | 1997-11-28 | 1997-11-28 | Astra Ab | New compounds |
| DE19948434A1 (de) | 1999-10-08 | 2001-06-07 | Gruenenthal Gmbh | Substanzbibliothek enthaltend bicyclische Imidazo-5-amine und/oder bicyclische Imidazo-3-amine |
| JP2001302667A (ja) * | 2000-04-28 | 2001-10-31 | Bayer Ag | イミダゾピリミジン誘導体およびトリアゾロピリミジン誘導体 |
| WO2001098685A1 (en) | 2000-06-19 | 2001-12-27 | Tay Armin S | Axial position changing transmission mechanism |
| GB0018473D0 (en) | 2000-07-27 | 2000-09-13 | Merck Sharp & Dohme | Therapeutic agents |
| DE10050663A1 (de) | 2000-10-13 | 2002-04-18 | Gruenenthal Gmbh | Verwendung von substituierten Imidazo[1,2-a]pyridin-, -pyrimidin- und pyrazin-3-yl-amin-Derivaten zur Herstellung von Medikamenten zur NOS-Inhibierung |
| WO2002101221A2 (en) | 2000-11-20 | 2002-12-19 | Cryoco, Inc. | A method and apparatus for the preparation and usage of a cryogenic propellant or explosive system |
| DK174233B1 (da) | 2000-12-27 | 2002-10-07 | Dss Danish Separation Systems | Sanitært spiralfilteranlæg |
| EP1363702A4 (en) * | 2001-01-30 | 2007-08-22 | Cytopia Pty Ltd | PROCESS FOR INHIBITING KINASES |
| GB0103926D0 (en) | 2001-02-17 | 2001-04-04 | Astrazeneca Ab | Chemical compounds |
| WO2002076985A1 (en) | 2001-03-23 | 2002-10-03 | Smithkline Beecham Corporation | Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases |
| US7003125B2 (en) | 2001-09-12 | 2006-02-21 | Seung-Hwan Yi | Micromachined piezoelectric microspeaker and fabricating method thereof |
| BR0307735A (pt) | 2002-02-19 | 2005-01-25 | Upjohn Co | Carboxamidas heteroaromáticas com ligação-n em ponte biciclìcas fundidas para o tratamento de doença |
| CN100537571C (zh) | 2002-04-19 | 2009-09-09 | 细胞基因组公司 | 咪唑并[1,2-а]吡嗪-8-基胺,其制备方法及使用方法 |
| US20040072081A1 (en) | 2002-05-14 | 2004-04-15 | Coleman Thomas P. | Methods for etching photolithographic reticles |
| US7288075B2 (en) | 2002-06-27 | 2007-10-30 | Ethicon, Inc. | Methods and devices utilizing rheological materials |
| JP2004053714A (ja) | 2002-07-17 | 2004-02-19 | Fuji Xerox Co Ltd | 画像定着装置及び画像定着方法 |
| US20040026867A1 (en) | 2002-08-09 | 2004-02-12 | Adams David J. | Bearing seal |
| US6761361B2 (en) | 2002-08-09 | 2004-07-13 | Credo Technology Corporation | Drill and drive apparatus with improved tool holder |
| WO2004022562A1 (en) | 2002-09-09 | 2004-03-18 | Cellular Genomics, Inc. | 6-ARYL-IMIDAZO[1,2-a]PYRAZIN-8-YLAMINES, METHOD OF MAKING, AND METHOD OF USE THEREOF |
| DE60317529T2 (de) | 2002-09-19 | 2008-09-25 | Schering Corp. | Imidazopyridine als hemmstoffe cyclin abhängiger kinasen |
| CN1694706A (zh) | 2002-09-23 | 2005-11-09 | 先灵公司 | 用作依赖细胞周期蛋白的激酶抑制剂的新的咪唑并吡嗪 |
| NZ538685A (en) | 2002-09-23 | 2008-02-29 | Schering Corp | Imidazopyrazines as cyclin dependent kinase inhibitors |
| JP4056346B2 (ja) | 2002-09-30 | 2008-03-05 | 三洋電機株式会社 | 非水電解質二次電池 |
| AU2003304204B2 (en) | 2002-10-29 | 2009-12-24 | Insmed Incorporated | Sustained release of antiinfectives |
| US7160885B2 (en) | 2003-02-10 | 2007-01-09 | Cgi Pharmaceuticals, Inc. | Certain 6, 8-(heteroaryl or aryl) disubstituted imidazo[1,2-a]pyrazines as modulators of Hsp90 complex activity |
| AR043002A1 (es) * | 2003-02-18 | 2005-07-13 | Altana Pharma Ag | Imidazopirazinas 6-substituidos |
| US7186832B2 (en) | 2003-02-20 | 2007-03-06 | Sugen Inc. | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors |
| US7157460B2 (en) * | 2003-02-20 | 2007-01-02 | Sugen Inc. | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors |
| US7456393B2 (en) | 2003-04-10 | 2008-11-25 | Ge Homeland Protection, Inc. | Device for testing surfaces of articles for traces of explosives and/or drugs |
| WO2005014599A1 (en) | 2003-06-04 | 2005-02-17 | Cellular Genomics, Inc. | Imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of bruton’s tyrosine kinase by such compounds |
| US20060183746A1 (en) * | 2003-06-04 | 2006-08-17 | Currie Kevin S | Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds |
| US7393848B2 (en) | 2003-06-30 | 2008-07-01 | Cgi Pharmaceuticals, Inc. | Certain heterocyclic substituted imidazo[1,2-A]pyrazin-8-ylamines and methods of inhibition of Bruton's tyrosine kinase by such compounds |
| US7259164B2 (en) | 2003-08-11 | 2007-08-21 | Cgi Pharmaceuticals, Inc. | Certain substituted imidazo[1,2-a]pyrazines, as modulators of kinase activity |
| US7236749B2 (en) | 2003-10-15 | 2007-06-26 | Honeywell International Inc. | Stuck microphone deselection system and method |
| WO2005047290A2 (en) * | 2003-11-11 | 2005-05-26 | Cellular Genomics Inc. | Imidazo[1,2-a] pyrazin-8-ylamines as kinase inhibitors |
| WO2005085252A1 (en) * | 2004-03-04 | 2005-09-15 | Biofocus Discovery Limited | Imidazo ‘1,2-a’ pyrazine compounds which interact with protein kinases |
| JP2006099930A (ja) | 2004-09-01 | 2006-04-13 | Tdk Corp | 情報記録媒体、記録再生装置およびスタンパー |
| US8145601B2 (en) | 2004-09-09 | 2012-03-27 | Microsoft Corporation | Method, system, and apparatus for providing resilient data transfer in a data protection system |
| JP2008516973A (ja) | 2004-10-15 | 2008-05-22 | タケダ サン ディエゴ インコーポレイテッド | キナーゼ阻害剤 |
| SG159549A1 (en) * | 2004-11-10 | 2010-03-30 | Cgi Pharmaceuticals Inc | Imidazo[1,2-a] pyrazin-8-ylamines useful as modulators of kinase activity |
| CN101124227A (zh) * | 2004-11-10 | 2008-02-13 | Cgi制药有限公司 | 可用作激酶活性调节剂的咪唑并[1,2-a]吡嗪-8-基胺 |
| JP4883959B2 (ja) | 2005-08-17 | 2012-02-22 | Ｎｔｎ株式会社 | 回転検出装置および回転検出装置付き軸受 |
| GB0520838D0 (en) * | 2005-10-13 | 2005-11-23 | Glaxo Group Ltd | Novel compounds |
| BRPI0618520A2 (pt) | 2005-11-10 | 2011-09-06 | Schering Corp | imidazopirazinas como inibidores de proteìna cinase |
| JP4837378B2 (ja) | 2006-01-04 | 2011-12-14 | 株式会社日立製作所 | データの改竄を防止する記憶装置 |
| US7446352B2 (en) | 2006-03-09 | 2008-11-04 | Tela Innovations, Inc. | Dynamic array architecture |
| DE102006032495A1 (de) | 2006-07-13 | 2008-02-07 | Nokia Siemens Networks Gmbh & Co.Kg | Verfahren und Vorrichtung zur Vermeidung von Interferenzen in einem zellulären Funkkommunikationssystem |
| US20080025821A1 (en) | 2006-07-25 | 2008-01-31 | Applied Materials, Inc. | Octagon transfer chamber |
| ES2549862T3 (es) | 2006-08-30 | 2015-11-02 | Cellzome Limited | Derivados de triazol como inhibidores de quinasa |
| ES2307402B1 (es) | 2006-10-30 | 2009-09-30 | Archivel Farma, S.L. | Vacuna profilactica contra la tuberculosis. |
| WO2008138843A1 (en) * | 2007-05-10 | 2008-11-20 | Galapagos N.V. | Imidazopyridines and triazolopyrimidines useful for the treatment of joint degenerative & inflammatory diseases |
| CN101952283B (zh) | 2007-12-14 | 2013-04-17 | 霍夫曼-拉罗奇有限公司 | 咪唑并[1，2-a]吡啶和咪唑并[1，2-b]哒嗪衍生物 |
| NZ587039A (en) * | 2008-02-13 | 2013-01-25 | Gilead Connecticut Inc | 6-aryl-imidazo[1, 2-a]pyrazine derivatives, method of making, and method of use thereof |
| JP5529852B2 (ja) * | 2008-05-06 | 2014-06-25 | ジリード コネティカット，インコーポレイティド | 置換アミド、その製造法及びＢｔｋインヒビターとしての使用 |
| CA2726460C (en) | 2008-07-15 | 2017-02-21 | F. Hoffmann-La Roche Ag | Novel phenyl-imidazopyridines and pyridazines |
| TWI453207B (zh) | 2008-09-08 | 2014-09-21 | Signal Pharm Llc | 胺基三唑并吡啶，其組合物及使用其之治療方法 |
| EP3552607A3 (en) | 2008-12-08 | 2020-01-15 | Gilead Connecticut, Inc. | Imidazopyrazine syk inhibitors |
| US8450321B2 (en) | 2008-12-08 | 2013-05-28 | Gilead Connecticut, Inc. | 6-(1H-indazol-6-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo-[1,2-A]pyrazin-8-amine, or a pharmaceutically acceptable salt thereof, as a SYK inhibitor |
| US8455493B2 (en) | 2008-12-08 | 2013-06-04 | Gilead Connecticut, Inc. | Imidazopyrazine Syk inhibitors |
| US20110099133A1 (en) | 2009-10-28 | 2011-04-28 | Industrial Technology Research Institute | Systems and methods for capturing and managing collective social intelligence information |
| KR101717809B1 (ko) | 2010-03-11 | 2017-03-17 | 질레드 코네티컷 인코포레이티드 | 이미다조피리딘 ｓｙｋ 억제제 |
| JP5554746B2 (ja) | 2011-05-06 | 2014-07-23 | 株式会社日立製作所 | ガス絶縁母線及びガス絶縁母線の異物除去方法 |
| US20140148430A1 (en) | 2012-11-26 | 2014-05-29 | Gilead Connecticut, Inc. | Imidazopyridines syk inhibitors |
-
2009
- 2009-12-07 US US12/632,140 patent/US8455493B2/en active Active
- 2009-12-07 DK DK13005979.3T patent/DK2716157T3/en active
- 2009-12-07 AU AU2009325132A patent/AU2009325132B2/en active Active
- 2009-12-07 EP EP13005979.3A patent/EP2716157B1/en active Active
- 2009-12-07 EP EP16164453.9A patent/EP3123864A1/en not_active Withdrawn
- 2009-12-07 CA CA2746023A patent/CA2746023C/en not_active Expired - Fee Related
- 2009-12-07 EA EA201690111A patent/EA201690111A1/ru unknown
- 2009-12-07 EA EA201190042A patent/EA020461B1/ru active IP Right Revival
- 2009-12-07 PL PL09832228T patent/PL2373169T3/pl unknown
- 2009-12-07 SI SI200931249T patent/SI2373169T1/sl unknown
- 2009-12-07 EP EP20090832228 patent/EP2373169B1/en active Active
- 2009-12-07 KR KR1020177014984A patent/KR20170066685A/ko not_active Ceased
- 2009-12-07 HU HUE13005979A patent/HUE030427T2/en unknown
- 2009-12-07 NZ NZ593459A patent/NZ593459A/xx not_active IP Right Cessation
- 2009-12-07 CN CN201510093652.9A patent/CN104744476B/zh active Active
- 2009-12-07 RS RS20160667A patent/RS55055B1/sr unknown
- 2009-12-07 JP JP2011539524A patent/JP5567587B2/ja active Active
- 2009-12-07 KR KR1020177002329A patent/KR20170013414A/ko not_active Ceased
- 2009-12-07 KR KR1020117015724A patent/KR101745732B1/ko active Active
- 2009-12-07 PE PE2014000121A patent/PE20140975A1/es active IP Right Grant
- 2009-12-07 SI SI200931503A patent/SI2716157T1/sl unknown
- 2009-12-07 VN VN201101623A patent/VN28228A1/vi unknown
- 2009-12-07 BR BRPI0922225-1A patent/BRPI0922225B1/pt not_active IP Right Cessation
- 2009-12-07 PL PL13005979T patent/PL2716157T3/pl unknown
- 2009-12-07 WO PCT/US2009/006445 patent/WO2010068257A1/en active Application Filing
- 2009-12-07 EA EA201400197A patent/EA024140B1/ru active IP Right Revival
- 2009-12-07 SG SG2011041241A patent/SG171991A1/en unknown
- 2009-12-07 MX MX2011006091A patent/MX2011006091A/es active IP Right Grant
- 2009-12-07 KR KR1020147035525A patent/KR101748925B1/ko active Active
- 2009-12-07 PT PT98322282T patent/PT2373169E/pt unknown
- 2009-12-07 LT LTEP13005979.3T patent/LT2716157T/lt unknown
- 2009-12-07 TW TW098141713A patent/TWI478922B/zh active
- 2009-12-07 ES ES09832228.2T patent/ES2545610T3/es active Active
- 2009-12-07 ES ES13005979.3T patent/ES2590804T3/es active Active
- 2009-12-07 CN CN200980156331.1A patent/CN102307474B/zh active Active
- 2009-12-07 PT PT130059793T patent/PT2716157T/pt unknown
- 2009-12-07 TW TW103135973A patent/TWI529172B/zh active
- 2009-12-07 PE PE2011001178A patent/PE20120058A1/es active IP Right Grant
-
2011
- 2011-06-05 IL IL213365A patent/IL213365A/en not_active IP Right Cessation
- 2011-06-07 CL CL2011001360A patent/CL2011001360A1/es unknown
- 2011-06-21 CO CO11077863A patent/CO6390078A2/es active IP Right Grant
-
2013
- 2013-04-23 US US13/868,971 patent/US8748607B2/en active Active
- 2013-04-23 US US13/868,967 patent/US8765761B2/en active Active
-
2014
- 2014-05-07 JP JP2014095907A patent/JP5832586B2/ja active Active
- 2014-05-09 US US14/274,618 patent/US9120811B2/en active Active
- 2014-06-09 US US14/300,189 patent/US9212191B2/en active Active
- 2014-08-27 IL IL234326A patent/IL234326A/en not_active IP Right Cessation
- 2014-11-23 IL IL235837A patent/IL235837A0/en unknown
-
2015
- 2015-08-12 JP JP2015159313A patent/JP6132445B2/ja active Active
- 2015-10-13 US US14/882,278 patent/US9796718B2/en active Active
-
2016
- 2016-08-05 SM SM201600267T patent/SMT201600267B/it unknown
- 2016-08-17 HR HRP20161036TT patent/HRP20161036T1/hr unknown
- 2016-08-18 CY CY20161100814T patent/CY1118377T1/el unknown
-
2017
- 2017-03-13 JP JP2017047354A patent/JP2017101090A/ja not_active Withdrawn
- 2017-09-28 US US15/719,399 patent/US20180086769A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20161036T1 (hr) | IMIDAZOPIRAZIN Syk INHIBITORI | |
| Kyriakopoulos et al. | Identification and treatment of T2-low asthma in the era of biologics | |
| Piret et al. | Viral interference between respiratory viruses | |
| KR102568333B1 (ko) | Jak 저해제 화합물을 사용하는 치료 방법 | |
| Just et al. | New perspectives of childhood asthma treatment with biologics | |
| Zhang et al. | NHBA isolated from Gastrodia elata exerts sedative and hypnotic effects in sodium pentobarbital-treated mice | |
| Ye et al. | Interleukin 22-producing CD4+ T cells in malignant pleural effusion | |
| JP2015505303A5 (hr) | ||
| Polosa et al. | Adenosine receptors as promising therapeutic targets for drug development in chronic airway inflammation | |
| Turner et al. | Effects of nebulised magnesium sulphate on inflammation and function of the guinea-pig airway | |
| Shook et al. | Recent advances in developing antiviral therapies for respiratory syncytial virus | |
| EP4126002A1 (en) | Methods of treating pulmonary injury with cgrp inhibitors | |
| Kong et al. | Efficacy and safety of chimeric antigen receptor T cell therapy in relapsed/refractory diffuse large B-cell lymphoma with different HBV status: a retrospective study from a single center | |
| AU2022255183A1 (en) | Apelin receptor modulators for treating age-related muscle conditions | |
| Smith et al. | Adenosine receptor subtypes in the airways responses to 5′‐adenosine monophosphate inhalation of sensitized guinea‐pigs | |
| Poynter | Do insights from mice imply that combined Th2 and Th17 therapies would benefit select severe asthma patients? | |
| Danese et al. | Editorial (Thematic Issue: New Mechanisms and Targets for IBD Therapy: Translational Gastroenterology Comes of Age) | |
| WO2014046624A1 (en) | A method for treating a disease or disorder of the lung by inhibition of the hedgehog pathway | |
| Sade et al. | Nitric oxide in asthma | |
| Obiefuna et al. | A novel A1 adenosine receptor antagonist (L-97-1) reduces allergic responses to house dust mite in an allergic rabbit model of asthma | |
| Naumov et al. | Peculiarities of TRPM8 and TRPA1 Expression in Macrophages Under M1-and M2-Polarization | |
| Dong et al. | The role of ICOSL in children with neutrophilic asthma | |
| Caramori et al. | Drugs for the Treatment of Airway Disease | |
| Domingos | Fernanda da Rocha Lapa, Ana Paula Ligeiro de Oliveira, Beatriz Golega Accetturi, Isabelli de Oliveira Martins | |
| Tsujimoto et al. | YM-254890, a Gαq/11 Inhibitor, Suppressed Airway Responses in Rodent Models. |